JAGOTEC AG Sample Clauses

JAGOTEC AG s/ Jacques Gonella ------------------- by: by: its: its:
Sample 1Sample 2See All (5)
AutoNDA by SimpleDocs
JAGOTEC AG a Swiss corporation having its place of business at Xxxxxxxxxxxxxxx 0 0, XX-0 000 Xxxxxxx, Xxxxxxxxxxx (hereinafter referred to as “Jagotec”);
Sample 1Sample 2Sample 3See All (4)
JAGOTEC AG. By: /s/ Jacques Gonella --------------------- Dr. Jacques Gonella President ------------------ * Confidential treatment rexxxxxxx. Xxx xxdacted material has been separaxxxx xxxxx xxxh the Commission. JAGO PHARMA AG hereby agrees to be bound by the provisions of sections 2.2, 6.3, 11.2.4.2, 11.4.3, 11.4.5, and 11.5 and article 16 of the * Development and Marketing Agreement and sections 11.2.4.2 and 11.5 of the above Agreement, agrees that all notices to be given to it shall be given to such address as is set forth in section 16.1 hereof unless and until it otherwise instructs APOTHECON in writing: JAGO PHARMA AG By: /s/ Jacques Gonella --------------------- Dr. Jacques Gonella President
Sample 1
JAGOTEC AG s/ Jacques Gonella /s/ -------------------------- -------------------------- By: By: Its: Its:
Sample 1
JAGOTEC AG. 6 Amounts paid by Jagotec during the Year for Active Material in respect of Product deficiencies in accordance with Section 3.12 and Recalls in accordance with Section 8 of the Agreement. Per: Name: SCHEDULE 4
Sample 1
JAGOTEC AG. By: /s/ Xxxxxxxxx Xxxxxxxx --------------------------------------- Name: Xxxxxxxxx Xxxxxxxx Position: Director JAGOTEC AG By: /s/ Xxxxxxx Halleisen --------------------------------------- Name: Xxxxxxx Halleisen Position: Director CRITICAL THERAPEUTICS, INC. By: /s/ Xxxx Xxxxx --------------------------------------- NAME: DR. XXXX XXXXX POSITION: PRESIDENT AND CHIEF EXECUTIVE OFFICER SCHEDULE 1 THE ZILEUTON REVISED PLAN AND TIMELINE [**] SCHEDULE 2 THE PATENTS [**]
Sample 1

Related to JAGOTEC AG

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Baxter and Nexell shall cooperate in any action taken by a third party solely involving a nullity action, opposition, reexamination or any other action taken by such third party alleging the invalidity or unenforceability of any Licensed Intellectual Property. Both parties agree to share equally in the cost of the defense of such Licensed Intellectual Property.

  • WHERXXX xx xxx xxxxxxx xxxxxx xx xxx xxxxxxxx, the Seller purchases certain retail installment sale contracts secured by new and used automobiles and light duty trucks from motor vehicle dealers.

  • Japan There are no country-specific provisions. Korea

  • FINLAND There are no country-specific provisions. FRANCE

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • India As used herein, “

  • BELGIUM NOTIFICATIONS

  • France No prospectus (including any amendment, supplement or replacement thereto) has been prepared in connection with the offering of the Securities that has been approved by the Autorité des marchés financiers or by the competent authority of another State that is a contracting party to the Agreement on the European Economic Area and notified to the Autorité des marchés financiers; each Underwriter represents and agrees that no Securities have been offered or sold nor will be offered or sold, directly or indirectly, to the public in France; each Underwriter represents and agrees that the prospectus or any other offering material relating to the Securities have not been distributed or caused to be distributed and will not be distributed or caused to be distributed to the public in France; such offers, sales and distributions have been and shall only be made in France to persons licensed to provide the investment service of portfolio management for the account of third parties, qualified investors (investisseurs qualifiés) and/or a restricted circle of investors (cercle restreint d’investisseurs), in each case investing for their own account, all as defined in Articles L. 411-2, D. 411-1, D. 411-2, D. 411-4, D. 734-1, D.744-1, D. 754-1 and D. 764-1 of the Code monétaire et financier. Each Underwriter represents and agrees that the direct or indirect distribution to the public in France of any so acquired Securities may be made only as provided by Articles L. 411-1, L. 411-2, L. 412-1 and L. 621-8 to L. 621-8-3 of the Code monétaire et financier and applicable regulations thereunder. Hong Kong Each Underwriter:

  • API A. Reliant shall supply to Cardinal Health for Manufacturing and Packaging, at Reliant’s sole cost, the API and applicable reference standards in quantities sufficient to meet Reliant’s requirements for each Product as further set forth in Article 4. Prior to delivery of any of the API or reference standard to Cardinal Health for Manufacturing and Packaging, Reliant shall provide to Cardinal Health a copy of the API Material Safety Data Sheet (“MSDS”), as amended, and any subsequent revisions thereto. Reliant shall supply the API, reference standards, and Certificate of Analysis FOB the Facility no later than thirty (30) days before the scheduled Manufacture Date upon which such API will be used by Cardinal Health. Upon receipt of the API, Cardinal Health shall conduct identification testing of the API. Cardinal Health shall use the API solely and exclusively for Manufacturing and Packaging under this Agreement. The maximum volume of API that Reliant supplies to Cardinal Health shall not exceed the amount reflected in the Firm Commitment and the next six (6) months of the Rolling Forecast.

Time is Money Join Law Insider Premium to draft better contracts faster.